Novartis said on Thursday it would acquire U.S.-based neuroscience company Cadent for up to $770 million, gaining full rights to Cadent's portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback